Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – ANORO ELLIPTA

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Umeklidinium Testmiljö

Umeklidinium

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. EMA. Incruse. Public Assessment Report 2014-02-20 https://goo.gl/110jlV

  2. Garne E, Hansen AV, Morris J, Zaupper L, Addor MC, Barisic I et al. Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study. J Allergy Clin Immunol. 2015;136:1496-1502e7.

  3. Källén B. The safety of asthma medications during pregnancy. Expert Opin Drug Saf 2007;6:15-26.

  4. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 3: Congenital malformations in the infants. Eur J Clin Pharmacol 2007;63:383-8.

  5. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 2: Infant characteristics excluding congenital malformations. Eur J Clin Pharmacol 2007;63:375-81.

  6. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 1: Maternal characteristics, pregnancy and delivery complications. Eur J Clin Pharmacol 2007;63:363-73.

  1. EMA. Incruse. Public Assessment Report 2014-02-20 https://goo.gl/110jlV
  2. Garne E, Hansen AV, Morris J, Zaupper L, Addor MC, Barisic I et al. Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study. J Allergy Clin Immunol. 2015;136:1496-1502e7.
  3. Källén B. The safety of asthma medications during pregnancy. Expert Opin Drug Saf 2007;6:15-26.
  4. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 3: Congenital malformations in the infants. Eur J Clin Pharmacol 2007;63:383-8.
  5. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 2: Infant characteristics excluding congenital malformations. Eur J Clin Pharmacol 2007;63:375-81.
  6. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 1: Maternal characteristics, pregnancy and delivery complications. Eur J Clin Pharmacol 2007;63:363-73.
2 2
2 2

Vilanterol Testmiljö

Vilanterol

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. EMA Assessment report. Relvar Ellipta (fluticasone furoate / vilanterol) 2013.

  2. Garne E, Hansen AV, Morris J, Zaupper L, Addor MC, Barisic I et al. Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study. J Allergy Clin Immunol. 2015;136:1496-1502e7.

  3. Ali Z, Hansen AV, Ulrik CS. Exacerbations of asthma during pregnancy: Impact on pregnancy complications and outcome. J Obstet Gynaecol. 2015:1-7.

  4. Lim A, Stewart K, König K, George J. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother. 2011;45:931-45.

  5. Källén B. The safety of asthma medications during pregnancy. Expert Opin Drug Saf 2007;6:15-26.

  6. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 3: Congenital malformations in the infants. Eur J Clin Pharmacol 2007;63:383-8.

  7. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 2: Infant characteristics excluding congenital malformations. Eur J Clin Pharmacol 2007;63:375-81.

  8. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 1: Maternal characteristics, pregnancy and delivery complications. Eur J Clin Pharmacol 2007;63:363-73.

  9. Liu S, Wen SW, Demissie K, Marcoux S, Kramer MS. Maternal asthma and pregnancy outcomes: A retrospective cohort study. Am J Obstet Gynecol 2001;184:90-6.

  10. Kallen B, Rydhstroem H, Aberg A. Asthma during pregnancy - a population based study. Eur J Epidemiol 2000;16:167-71.

  1. EMA Assessment report. Relvar Ellipta (fluticasone furoate / vilanterol) 2013.
  2. Garne E, Hansen AV, Morris J, Zaupper L, Addor MC, Barisic I et al. Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study. J Allergy Clin Immunol. 2015;136:1496-1502e7.
  3. Ali Z, Hansen AV, Ulrik CS. Exacerbations of asthma during pregnancy: Impact on pregnancy complications and outcome. J Obstet Gynaecol. 2015:1-7.
  4. Lim A, Stewart K, König K, George J. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother. 2011;45:931-45.
  5. Källén B. The safety of asthma medications during pregnancy. Expert Opin Drug Saf 2007;6:15-26.
  6. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 3: Congenital malformations in the infants. Eur J Clin Pharmacol 2007;63:383-8.
  7. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 2: Infant characteristics excluding congenital malformations. Eur J Clin Pharmacol 2007;63:375-81.
  8. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 1: Maternal characteristics, pregnancy and delivery complications. Eur J Clin Pharmacol 2007;63:363-73.
  9. Liu S, Wen SW, Demissie K, Marcoux S, Kramer MS. Maternal asthma and pregnancy outcomes: A retrospective cohort study. Am J Obstet Gynecol 2001;184:90-6.
  10. Kallen B, Rydhstroem H, Aberg A. Asthma during pregnancy - a population based study. Eur J Epidemiol 2000;16:167-71.